Lymphoplasmacytic lymphoma primary prevention: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Lymphoplasmacytic lymphoma}} {{CMG}}; {{AE}} ==Overview== There are no established measures for the primary prevention of [disease name]. OR There are no avail...") |
|||
| (13 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Lymphoplasmacytic lymphoma}} | {{Lymphoplasmacytic lymphoma}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{S.M.}} | ||
==Overview== | ==Overview== | ||
[[Primary prevention]] of [[lymphoplasmacytic lymphoma]] depends on avoiding the type of modifiable [[risk factor]] [[Causes|causing]] the [[disease]] such as [[hepatitis C]], [[HIV]], [[rickettsiosis]], [[hay fever]], [[human]] T-lymphotropic [[virus]] type 1 [[infection]], [[Epstein Barr virus|epstein-Barr virus]] [[infection]], [[Environmental factor|environmental factors]], [[History and Physical examination|history]] of [[helicobacter pylori]] [[infection]], [[History and Physical examination|history]] of [[immunosuppressant]] [[drug therapy]] after an [[organ transplant]], [[diet]] [[Rich focus|rich]] in meat and [[fat]] and [[History and Physical examination|history]] of past [[Treatments|treatment]] for [[hodgkin lymphoma]]. | |||
[ | |||
==Primary Prevention== | ==Primary Prevention== | ||
[[Primary prevention]] of [[lymphoplasmacytic lymphoma]] depends on the type of [[risk factor]] [[Causes|causing]] the [[disease]].<ref name="PP">Waldenström's macroglobulinemia. American Cancer Society. (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-prevention Accessed on November 11, 2015</ref> | |||
===Modifiable risk factors:=== | |||
*[[Hepatitis C]]<ref name="pmid18809818">{{cite journal| author=Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O| title=Chronic immune stimulation and subsequent Waldenström macroglobulinemia. | journal=Arch Intern Med | year= 2008 | volume= 168 | issue= 17 | pages= 1903-9 | pmid=18809818 | doi=10.1001/archinternmed.2008.4 | pmc=2670401 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18809818 }} </ref><ref name="pmid18387498">{{cite journal| author=de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM et al.| title=Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. | journal=Clin Gastroenterol Hepatol | year= 2008 | volume= 6 | issue= 4 | pages= 451-8 | pmid=18387498 | doi=10.1016/j.cgh.2008.02.011 | pmc=3962672 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18387498 }} </ref><ref name="pmid20181958">{{cite journal| author=Kristinsson SY, Koshiol J, Björkholm M, Goldin LR, McMaster ML, Turesson I et al.| title=Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. | journal=J Natl Cancer Inst | year= 2010 | volume= 102 | issue= 8 | pages= 557-67 | pmid=20181958 | doi=10.1093/jnci/djq043 | pmc=2857799 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20181958 }} </ref><ref name="pmid18263783">{{cite journal| author=Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J et al.| title=Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. | journal=Blood | year= 2008 | volume= 111 | issue= 8 | pages= 4029-38 | pmid=18263783 | doi=10.1182/blood-2007-10-119974 | pmc=2288717 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18263783 }} </ref><ref name="pmid16985251">{{cite journal| author=Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH et al.| title=Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. | journal=J Natl Cancer Inst | year= 2006 | volume= 98 | issue= 18 | pages= 1321-30 | pmid=16985251 | doi=10.1093/jnci/djj361 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16985251 }} </ref> | |||
*[[HIV]] | |||
*[[Rickettsiosis]] | |||
*[[Hay fever]] | |||
*[[Human]] T-lymphotropic [[virus]] type 1 [[infection]] | |||
*[[Epstein Barr virus|Epstein-Barr virus]] [[infection]] | |||
*[[Environmental factor|Environmental factors]]:<ref name="pmid25174029">{{cite journal| author=Vajdic CM, Landgren O, McMaster ML, Slager SL, Brooks-Wilson A, Smith A et al.| title=Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. | journal=J Natl Cancer Inst Monogr | year= 2014 | volume= 2014 | issue= 48 | pages= 87-97 | pmid=25174029 | doi=10.1093/jncimonographs/lgu002 | pmc=4155457 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25174029 }} </ref> | |||
*[ | **[[Occupational Medicine|Occupational]] (Farming) | ||
*[ | **[[Pesticides]] | ||
*[ | ** Paint | ||
** Rubber [[dyes]] | |||
**[[Benzene]] | |||
**[[Coal tar|Coal]] [[dust]] | |||
[ | ** Leather manufacturing | ||
*[ | **[[Wood]] [[dust]] | ||
*[ | **[[Organic solvents]] | ||
*[ | *[[History and Physical examination|History]] of [[Helicobacter pylori]] [[infection]] | ||
*[[History and Physical examination|History]] of [[immunosuppressant]] [[drug therapy]] after an [[organ transplant]] | |||
*[[Diet]] [[Rich focus|rich]] in meat and [[fat]] | |||
*[[History and Physical examination|History]] of past [[Treatments|treatment]] for [[Hodgkin lymphoma]] | |||
==References== | ==References== | ||
| Line 44: | Line 35: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | |||
[[Category:Blood]] | |||
[[Category:Hematology]] | |||
Latest revision as of 13:50, 30 October 2019
|
Lymphoplasmacytic lymphoma Microchapters |
|
Differentiating Lymphoplasmacytic Lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Lymphoplasmacytic lymphoma primary prevention On the Web |
|
American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma primary prevention |
|
Risk calculators and risk factors for Lymphoplasmacytic lymphoma primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]
Overview
Primary prevention of lymphoplasmacytic lymphoma depends on avoiding the type of modifiable risk factor causing the disease such as hepatitis C, HIV, rickettsiosis, hay fever, human T-lymphotropic virus type 1 infection, epstein-Barr virus infection, environmental factors, history of helicobacter pylori infection, history of immunosuppressant drug therapy after an organ transplant, diet rich in meat and fat and history of past treatment for hodgkin lymphoma.
Primary Prevention
Primary prevention of lymphoplasmacytic lymphoma depends on the type of risk factor causing the disease.[1]
Modifiable risk factors:
- Hepatitis C[2][3][4][5][6]
- HIV
- Rickettsiosis
- Hay fever
- Human T-lymphotropic virus type 1 infection
- Epstein-Barr virus infection
- Environmental factors:[7]
- Occupational (Farming)
- Pesticides
- Paint
- Rubber dyes
- Benzene
- Coal dust
- Leather manufacturing
- Wood dust
- Organic solvents
- History of Helicobacter pylori infection
- History of immunosuppressant drug therapy after an organ transplant
- Diet rich in meat and fat
- History of past treatment for Hodgkin lymphoma
References
- ↑ Waldenström's macroglobulinemia. American Cancer Society. (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-prevention Accessed on November 11, 2015
- ↑ Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O (2008). "Chronic immune stimulation and subsequent Waldenström macroglobulinemia". Arch Intern Med. 168 (17): 1903–9. doi:10.1001/archinternmed.2008.4. PMC 2670401. PMID 18809818.
- ↑ de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM; et al. (2008). "Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium". Clin Gastroenterol Hepatol. 6 (4): 451–8. doi:10.1016/j.cgh.2008.02.011. PMC 3962672. PMID 18387498.
- ↑ Kristinsson SY, Koshiol J, Björkholm M, Goldin LR, McMaster ML, Turesson I; et al. (2010). "Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia". J Natl Cancer Inst. 102 (8): 557–67. doi:10.1093/jnci/djq043. PMC 2857799. PMID 20181958.
- ↑ Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J; et al. (2008). "Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium". Blood. 111 (8): 4029–38. doi:10.1182/blood-2007-10-119974. PMC 2288717. PMID 18263783.
- ↑ Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH; et al. (2006). "Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia". J Natl Cancer Inst. 98 (18): 1321–30. doi:10.1093/jnci/djj361. PMID 16985251.
- ↑ Vajdic CM, Landgren O, McMaster ML, Slager SL, Brooks-Wilson A, Smith A; et al. (2014). "Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project". J Natl Cancer Inst Monogr. 2014 (48): 87–97. doi:10.1093/jncimonographs/lgu002. PMC 4155457. PMID 25174029.